Clinical trial reveals twice-yearly injection reduces risk of HIV infection by 96% Medical XpressGilead’s twice-yearly lenacapavir shows promise in HIV prevention trial Yahoo FinanceHIV Breakthrough as New Injection 89% More Effective Than PrEP NewsweekGilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results BioSpaceTwice-Yearly Injection 96% Effective in Preventing HIV Infection U.S.